Mirum Pharmaceuticals IPO

7/17/2019

IPO

$75,000,000

Per the firm's latest filing, it plans to use the net proceeds from the IPO and cash on hand as follows: approximately $95.0 million to $105.0 million to further the clinical development of maralixibat, including our planned Phase 3 clinical trials in PFIC and ALGS and our anticipated clinical program in BA; approximately $30.0 million to $40.0 million to further the clinical development of volixibat, including our planned Phase 2 clinical trials in ICP and PSC; and the remainder for other ongoing research and development activities, and for general corporate purposes, including working capital, operating expenses and capital expenditures.

Publicly-held

Biopharmaceutical

950 Tower Ln. 1050
Foster City, CA 94404
USA

Mirum Pharmaceuticals Inc. (Nasdaq: MIRM) is a therapeutics company developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.